Cullinan Therapeutics, Inc.
NASDAQ:CGEMMedical - Pharmaceuticals
+$0.62 today
- Market cap
- $584.94M
- Beta
- 0.01
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$3.73
Volume 1.06M
Average 0.99M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
Intrinsic Alpha fair value
Locked
Current Price
$9.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Legend Biotech Corporation NASDAQ:LEGN | $3.24B | $17.50 | Not rated | -21.4 | -41.96% |
Xencor, Inc. NASDAQ:XNCR | $2.78B | $37.09 | Not rated | -5.5 | +118.07% |
Nurix Therapeutics, Inc. NASDAQ:NRIX | $1.69B | $15.48 | Undervalued | -6.4 | -1.61% |
Immatics N.V. NASDAQ:IMTX | $956.17M | $6.39 | Not rated | -5.3 | -40.95% |
Janux Therapeutics, Inc. NASDAQ:JANX | $695.66M | $11.37 | Not rated | -7.6 | -64.21% |
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | $672.92M | $13.01 | Not rated | -9.8 | -45.58% |
Compugen Ltd. NASDAQ:CGEN | $198.92M | $2.10 | Undervalued | 5.4 | +22.50% |
ADC Therapeutics S.A. NYSE:ADCT | $171.07M | $1.34 | Not rated | -1.2 | -65.92% |
ALX Oncology Holdings Inc. NASDAQ:ALXO | $143.81M | $1.04 | Not rated | -0.9 | -34.01% |
MacroGenics, Inc. NASDAQ:MGNX | $140.14M | $2.20 | Not rated | -3.6 | +38.73% |
Continue the stock analysis
Jump to another research area for this company.